Thank you for taking part

Thank you for taking our short knowledge awareness survey, designed to help you refresh and build upon your knowledge of ulcerative colitis.

1. Aside from corticosteroids, which of the following treatment options are recommended for inducing remission in moderate-to-severe UC, according to current European and US guidelines for UC management?

TNF-α inhibitors (infliximab, adalimumab, golimumab), anti-integrin agent (vedolizumab), IL‑12/23 inhibitor (ustekinumab) or JAK inhibitor (tofacitinib)

2. Jerome has asked for information about more recently approved UC treatments, such as the IL-23 inhibitor mirikizumab, JAK inhibitors upadacitinib and filgotinib, and the S1PR modulator ozanimod.

In the clinical trials that supported regulatory approval of mirikizumab, upadacitinib, filgotinib and ozanimod for the treatment of moderate-to-severe UC in Europe and/or the US, the primary endpoint was:

Clinical remission, defined by the Mayo or modified Mayo score, at the end of the induction and maintenance phases

3. What are key considerations that can inform whether recently approved biologics and targeted small molecules could be appropriate for Jerome (aside from disease severity and extent, and the regulatory-approved indications for each treatment)?

The risks and benefits of each treatment for Jerome, considering his comorbidities, as well as his needs and preferences, and treatment availability

4. What is the primary aim of developing new treatments to help address unmet needs in moderate-to-severe and refractory UC?

Achieving and maintaining remission in a larger proportion of patients, and limiting corticosteroid use and the requirement for surgery

Thank you for participating in this quiz!